Bacil Pharma

how big is Bacil Pharma?

As of May 05, Bacil Pharma Ltd has a market capitalization of 24.00 Cr, categorizing it as a Micro Cap company, with net sales of 0.00 Cr and a net profit of 0.35 Cr over the latest four quarters. Shareholder's funds are reported at 1.21 Cr, and total assets amount to 1.27 Cr as of the latest annual period ending in Mar'24.

Market Cap: As of May 05, Bacil Pharma Ltd has a market capitalization of 24.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Dec'24, Sep'24, Jun'24, and Mar'24, is 0.00 Cr. The sum of Net Profit for the same quarters is 0.35 Cr. This data is presented on a Standalone basis.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 1.21 Cr, while Total Assets amount to 1.27 Cr.

Is Bacil Pharma overvalued or undervalued?

As of November 17, 2023, Bacil Pharma is considered risky and overvalued with a PE ratio of 24.47 and a troubling ROCE of -13.29%, despite a strong one-year stock return of 70.54%, contrasting with a year-to-date decline of 27.35%.

As of 17 November 2023, Bacil Pharma's valuation grade has moved from does not qualify to risky, indicating a shift in its perceived financial health. The company appears to be overvalued given its current metrics, particularly with a PE ratio of 24.47, a Price to Book Value of 14.48, and a troubling ROCE of -13.29%. These figures suggest that the stock may not be justified at its current price level.<BR><BR>In comparison to its peers, Bacil Pharma's valuation stands out unfavorably; for instance, MMTC has a PE ratio of 119.39, while PTC India, which is rated very attractive, has a significantly lower PE of 9.02. The PEG ratio for Bacil Pharma is notably low at 0.03, which could indicate potential growth, but the negative EV to EBIT and EV to EBITDA ratios of -24.51 raise serious concerns about profitability. Despite a strong one-year stock return of 70.54%, the year-to-date performance shows a decline of 27.35%, contrasting sharply with the Sensex's positive return of 5.63% in the same period, reinforcing the notion that Bacil Pharma may be overvalued.

What is the technical trend for Bacil Pharma?

As of May 26, 2025, Bacil Pharma shows a mildly bullish trend due to daily moving averages and monthly MACD signals, but mixed indicators from weekly MACD and Bollinger Bands suggest caution.

As of 26 May 2025, the technical trend for Bacil Pharma has changed from does not qualify to mildly bullish. The current stance is mildly bullish, driven by a bullish signal from the daily moving averages and a bullish monthly MACD. However, the weekly MACD and Bollinger Bands indicate a mildly bearish sentiment, suggesting some caution. The KST is bearish on the weekly but bullish on the monthly, adding to the mixed signals. Overall, while there are bullish indicators, the presence of bearish signals in the weekly timeframe indicates a lack of strong momentum.

How has been the historical performance of Bacil Pharma?

Bacil Pharma has not generated revenue from March 2019 to March 2025 but improved its financial position by reducing total expenditure and achieving a profit after tax of 0.40 crore in March 2025, recovering from previous losses. Additionally, total assets increased significantly from 1.27 crore in March 2024 to 25.55 crore in March 2025, indicating better asset management.

Answer:<BR>The historical performance of Bacil Pharma shows a consistent lack of revenue generation over the years, with net sales and other operating income remaining at zero from March 2019 to March 2025. Despite this, the company has seen a significant improvement in its profit metrics, achieving a profit after tax of 0.40 crore in March 2025, a notable recovery from losses in previous years, including a loss of 3.86 crore in March 2022. The total expenditure has decreased from 3.92 crore in March 2022 to 0.25 crore in March 2025, indicating improved cost management. The company's total assets have increased dramatically from 1.27 crore in March 2024 to 25.55 crore in March 2025, primarily driven by a rise in non-current investments. <BR><BR>Breakdown:<BR>Bacil Pharma's financial history reveals a persistent absence of sales and operating income from March 2019 through March 2025, with total operating income consistently recorded at zero. However, the company has made strides in reducing its total expenditure, which fell significantly from 3.92 crore in March 2022 to 0.25 crore in March 2025. This reduction in expenses has contributed to a turnaround in profitability, as evidenced by the profit after tax reaching 0.40 crore in March 2025, compared to substantial losses in prior years. The company's total assets have surged from 1.27 crore in March 2024 to 25.55 crore in March 2025, largely due to an increase in non-current investments, reflecting a strategic shift in asset allocation. Overall, while Bacil Pharma has not generated revenue, its improved financial management and asset growth indicate a potential for future stability.

When is the next results date for Bacil Pharma Ltd?

The next results date for Bacil Pharma Ltd is 13 February 2026.

The next results date for Bacil Pharma Ltd is scheduled for 13 February 2026.

Why is Bacil Pharma Ltd falling/rising?

As of 17-Mar, Bacil Pharma Ltd's stock price is at 48.48, down 0.74% and underperforming its sector by 1.21%. The significant drop in investor participation and current price dynamics indicate a lack of interest, contributing to the stock's recent decline despite strong long-term performance.

As of 17-Mar, Bacil Pharma Ltd's stock price is currently at 48.48, reflecting a decrease of 0.36 or 0.74%. The stock has underperformed its sector by 1.21% today, indicating a relative weakness compared to its peers. Additionally, the stock has experienced a significant drop in investor participation, with delivery volume on 16 March falling by 99.11% compared to the 5-day average. This decline in trading activity suggests a lack of interest from investors, which can contribute to downward pressure on the stock price.<BR><BR>Despite the recent decline, Bacil Pharma Ltd has shown strong performance over longer periods, with a year-to-date increase of 36.03% and a remarkable 673.21% rise over the past three years. However, the current price is lower than the 5-day moving averages, although it remains above the 20, 50, 100, and 200-day moving averages, indicating some volatility in the short term. Overall, the combination of underperformance in today's trading, reduced investor participation, and the current price dynamics are contributing factors to the stock's recent decline.

Why is Bacil Pharma Ltd falling/rising?

As of 18-Mar, Bacil Pharma Ltd's stock price is at 48.39, down 0.29% and underperforming its sector. Despite strong long-term gains, recent trends show a decline in value and investor participation, indicating short-term weakness.

As of 18-Mar, Bacil Pharma Ltd's stock price is currently at 48.39, reflecting a decrease of 0.14, or 0.29%. The stock has been underperforming in the market, having lost value for the last two consecutive days, resulting in a total decline of 0.92% during this period. Additionally, the stock's performance today has underperformed its sector by 1.78%. <BR><BR>Despite a strong performance over longer periods, such as a year-to-date increase of 35.77% and a three-year increase of 671.77%, the recent trend indicates a decline. This is further supported by a significant drop in investor participation, with delivery volume on 17 March falling by 89.6% compared to the five-day average. <BR><BR>While the stock remains above its 20-day, 50-day, 100-day, and 200-day moving averages, it is currently below its 5-day moving average, suggesting a short-term weakness. Overall, these factors contribute to the current decline in Bacil Pharma Ltd's stock price.

Why is Bacil Pharma Ltd falling/rising?

As of 19-Mar, Bacil Pharma Ltd's stock price is rising to Rs 48.98, up 2.25%, and has outperformed its sector today. Despite a decline in investor participation, the stock shows a strong bullish trend and a year-to-date increase of 37.43%.

As of 19-Mar, Bacil Pharma Ltd's stock price is rising, currently at Rs 48.98, reflecting a change of Rs 1.08 or 2.25%. This upward movement is notable as the stock has outperformed the sector by 5.86% today. The stock opened with a significant gain of 4.18% and reached an intraday high of Rs 49.9. Additionally, Bacil Pharma is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong bullish trend.<BR><BR>Moreover, the stock has shown resilience by gaining after two consecutive days of decline, suggesting a potential trend reversal. Despite a decrease in overall trading activity in the sector, Bacil Pharma's performance remains robust, with a year-to-date increase of 37.43%, significantly outperforming the Sensex, which has declined by 12.92% in the same period. However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 51.22% against the 5-day average, which could indicate a need for caution moving forward.

Why is Bacil Pharma Ltd falling/rising?

As of 20-Mar, Bacil Pharma Ltd's stock price is rising to Rs 49.49, with a year-to-date increase of 38.86%, significantly outperforming the Sensex. Despite a decline in investor participation, the stock shows strong upward momentum and is close to its 52-week high.

As of 20-Mar, Bacil Pharma Ltd's stock price is rising, currently at Rs 49.49, reflecting an increase of Rs 0.94 or 1.94%. The stock has shown strong performance over various periods, with a year-to-date increase of 38.86%, significantly outperforming the Sensex, which has decreased by 12.54% in the same timeframe. Additionally, the stock has gained 4.79% over the past week, while the Sensex has remained nearly flat with a change of -0.04%.<BR><BR>Today, Bacil Pharma is close to its 52-week high, being only 4.87% away from Rs 51.9, and it has outperformed its sector by 0.39%. The stock has been on a positive trend, gaining for the last two days with a total return of 3.32% during this period. Furthermore, Bacil Pharma is trading above its moving averages across multiple timeframes, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a strong upward momentum.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume dropping by 49.81% against the 5-day average. Despite this decrease in participation, the stock remains liquid enough for trading. Overall, the combination of strong historical performance, proximity to a 52-week high, and consistent gains contributes to the rising stock price of Bacil Pharma Ltd.

Why is Bacil Pharma Ltd falling/rising?

As of 23-Mar, Bacil Pharma Ltd's stock price is currently Rs 47.55, reflecting a 3.92% decline after a trend reversal. Despite outperforming the sector today, the stock shows a short-term downward trend amid increased volatility and significant trading activity at lower prices.

As of 23-Mar, Bacil Pharma Ltd's stock price is falling, currently at Rs 47.55, which reflects a decrease of Rs 1.94 or 3.92%. This decline follows a trend reversal after two consecutive days of gains. Although the stock opened with a gain of 4.65% today and reached an intraday high of Rs 51.79, it also experienced a significant drop to a low of Rs 47.02, indicating volatility within the trading session.<BR><BR>In terms of performance relative to the broader market, Bacil Pharma Ltd has outperformed the sector by 1.09% today, but the overall trading environment has been challenging, with the sector experiencing a decline of 5.03%. Despite this, the stock has shown strong year-to-date growth of 33.42%, contrasting with the Sensex's decline of 14.70% over the same period. However, the recent price drop could be attributed to the stock trading in a wide range and the weighted average price being closer to the day's low, suggesting that more volume was traded at lower prices.<BR><BR>Additionally, while there has been a notable increase in investor participation, with delivery volume rising by 482.23% against the 5-day average, the stock's current performance indicates a short-term downward trend. This combination of factors contributes to the observed decline in Bacil Pharma Ltd's stock price.

Why is Bacil Pharma Ltd falling/rising?

As of 24-Mar, Bacil Pharma Ltd's stock price is rising to Rs 48.76, up by 2.54%. This increase is driven by strong performance, positive trading trends, and heightened investor interest.

As of 24-Mar, Bacil Pharma Ltd's stock price is rising, currently at Rs 48.76, reflecting an increase of Rs 1.21 or 2.54%. This upward movement can be attributed to several key factors. <BR><BR>Firstly, the stock has shown strong performance today, outperforming its sector by 1.65%. It opened with a significant gain of 3.05% and reached an intraday high of Rs 49. Additionally, Bacil Pharma is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in its price movement.<BR><BR>Moreover, there has been a notable increase in investor participation, with a delivery volume of 11.99k on 23 March, which is up by 88.06% compared to the 5-day average. This suggests heightened interest and confidence among investors in the stock.<BR><BR>Overall, these factors contribute to the rising stock price of Bacil Pharma Ltd, reflecting positive market sentiment and strong trading activity.

Why is Bacil Pharma Ltd falling/rising?

As of 25-Mar, Bacil Pharma Ltd's stock price is at 49.00, reflecting a 0.76% increase and a 3.05% gain over the last two days. The stock is trading above its moving averages, indicating a strong upward trend, despite a slight underperformance in its sector today.

As of 25-Mar, Bacil Pharma Ltd's stock price is rising, currently at 49.00, reflecting an increase of 0.37 (0.76%). The stock has shown a positive performance over the last two days, gaining 3.05% during this period. Additionally, it has outperformed the benchmark Sensex over the past week, with a return of +2.30% compared to the Sensex's -1.87%. <BR><BR>Bacil Pharma is also trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a strong upward trend. Furthermore, there has been a notable increase in investor participation, with delivery volume rising by 17.54% against the 5-day average, suggesting growing interest in the stock. <BR><BR>Despite underperforming its sector by -1.74% today, the overall positive trends in both short-term gains and investor activity contribute to the stock's rising price.

Which are the latest news on Bacil Pharma?